Liquidia Faces Investor Investigation Over Patent Dispute
Levi & Korsinsky LLP is investigating Liquidia Corporation (LQDA) on behalf of investors who lost money after a court ruled Yutrepia infringed two patents. The probe includes the company's revenue forecasts.
Law firm Levi & Korsinsky LLP has initiated an investigation into Liquidia Corporation (LQDA). The probe is focused on shareholders who may have incurred financial losses following a court's determination that the company's drug Yutrepia infringed upon two valid patent claims held by United Therapeutics.
The investigation will examine whether Liquidia has a liability to compensate investors for their losses. This includes scrutinizing the company's own forecast predicting over $1 billion in net revenue by 2027. The outcome of the patent dispute has impacted the company's stock value.
The patent litigation is significant for Liquidia, as it pertains to their drug Yutrepia. The court's ruling suggests that the drug's market entry may face obstacles or that its commercialization carries substantial risks due to the patent infringement.
The investigating law firm is seeking information from all Liquidia Corporation shareholders who experienced losses after purchasing the company's stock before a specified date. The purpose is to gather further details for a potential legal action.